Vincent Gatinois

Dr. Vincent Gatinois

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2020 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
KGKasper Gadsbøll
Kasper Gadsbøll
OPOlav Bjørn Petersen
Olav Bjørn Petersen
VGVincent Gatinois
Vincent Gatinois
HSHeather Strange
Heather Strange
BJBo Jacobsson
Bo Jacobsson
IVIda Vogel
Ida Vogel

15 June 2016 in Human Mutation
Verified
Journal Article
Closed access
PDF file
NBNina Bögershausen
Nina Bögershausen
VGVincent Gatinois
Vincent Gatinois
VRVera Riehmer
Vera Riehmer
HKHülya Kayserili
Hülya Kayserili
JBJutta Becker
Jutta Becker
BWBernd Wollnik
Bernd Wollnik
Kabuki syndrome (KS) is a rare but recognizable condition that consists of a characteristic face, short stature, various organ malformations, and a variable degree of intellectual disability. Mutations in KMT2D have been identified as the main cause for KS, whereas mutations in KDM6A are a much less frequent cause. Here, we report a mutation screening in a case series of 347 unpublished patients, in which we identified 12 novel KDM6A mutations (KS type 2) and 208 mutations in KMT2D (KS type 1), 132 of them novel. Two of the KDM6A mutations were maternally inherited and nine were shown to be de novo. We give an up‐to‐date overview of all published mutations for the two KS genes and point out possible mutation hot spots and strategies for molecular genetic testing. We also report the clinical details for 11 patients with KS type 2, summarize the published clinical information, specifically with a focus on the less well‐defined X‐linked KS type 2, and comment on phenotype–genotype correlations as well as sex‐specific phenotypic differences. Finally, we also discuss a possible role of KDM6A in Kabuki‐like Turner syndrome and report a mutation screening of KDM6C (UTY) in male KS patients.

21 October 2015 in Human Mutation
Verified
Journal Article
Closed access
PDF file
MBMouna Barat-Houari
Mouna Barat-Houari
GSGuillaume Sarrabay
Guillaume Sarrabay
VGVincent Gatinois
Vincent Gatinois
AFAurélie Fabre
Aurélie Fabre
BDBruno Dumont
Bruno Dumont
ITIsabelle Touitou
Isabelle Touitou
Mutations in the COL2A1 gene cause a spectrum of rare autosomal-dominant conditions characterized by skeletal dysplasia, short stature, and sensorial defects. An early diagnosis is critical to providing relevant patient care and follow-up, and genetic counseling to affected families. There are no recent exhaustive descriptions of the causal mutations in the literature. Here, we provide a review of COL2A1 mutations extracted from the Leiden Open Variation Database (LOVD) that we updated with data from PubMed and our own patients. Over 700 patients were recorded, harboring 415 different mutations. One-third of the mutations are dominant-negative mutations that affect the glycine residue in the G-X-Y repeats of the alpha 1 chain. These mutations disrupt the collagen triple helix and are common in achondrogenesis type II and hypochondrogenesis. The mutations resulting in a premature stop codon are found in less severe phenotypes such as Stickler syndrome. The p.(Arg275Cys) substitution is found in all patients with COL2A1-associated Czech dysplasia. LOVD-COL2A1 provides support and potential collaborative material for scientific and clinical projects aimed at elucidating phenotype–genotype correlation and differential diagnosis in patients with type II collagenopathies.

8 September 2016 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AGAlice Goldenberg
Alice Goldenberg
FRFlorence Riccardi
Florence Riccardi
ATAude Tessier
Aude Tessier
RPRolph Pfundt
Rolph Pfundt
TBTiffany Busa
Tiffany Busa
NPNicole Philip
Nicole Philip

23 October 2017 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
ATAnne-Claude Tabet
Anne-Claude Tabet
TRThomas Rolland
Thomas Rolland
MDMarie Ducloy
Marie Ducloy
JLJonathan Levy
Jonathan Levy
JBJulien Buratti
Julien Buratti
TBThomas Bourgeron
Thomas Bourgeron
Phelan-McDermid syndrome (PMS) is characterized by a variety of clinical symptoms with heterogeneous degrees of severity, including intellectual disability (ID), absent or delayed speech, and autism spectrum disorders (ASD). It results from a deletion of the distal part of chromosome 22q13 that in most cases includes the SHANK3 gene. SHANK3 is considered a major gene for PMS, but the factors that modulate the severity of the syndrome remain largely unknown. In this study, we investigated 85 patients with different 22q13 rearrangements (78 deletions and 7 duplications). We first explored the clinical features associated with PMS, and provide evidence for frequent corpus callosum abnormalities in 28% of 35 patients with brain imaging data. We then mapped several candidate genomic regions at the 22q13 region associated with high risk of clinical features, and suggest a second locus at 22q13 associated with absence of speech. Finally, in some cases, we identified additional clinically relevant copy-number variants (CNVs) at loci associated with ASD, such as 16p11.2 and 15q11q13, which could modulate the severity of the syndrome. We also report an inherited SHANK3 deletion transmitted to five affected daughters by a mother without ID nor ASD, suggesting that some individuals could compensate for such mutations. In summary, we shed light on the genotype-phenotype relationship of patients with PMS, a step towards the identification of compensatory mechanisms for a better prognosis and possibly treatments of patients with neurodevelopmental disorders.

1 December 2014 in Fertility and Sterility
Verified
Journal Article
Closed access
FPFranck PELLESTOR
Franck PELLESTOR
VGVincent Gatinois
Vincent Gatinois
JPJacques Puechberty
Jacques Puechberty
DGDavid Geneviève
David Geneviève
GLGeneviève Lefort
Geneviève Lefort